Navigation Links
Dynatronics Receives 180-Day NASDAQ Extension
Date:12/10/2009

SALT LAKE CITY, Dec. 10 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that following last month's panel hearing, NASDAQ granted Dynatronics a full 180-day extension for regaining compliance with the $1.00 minimum bid requirement.

"We are pleased the panel granted us the full 180-day extension we requested," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This will allow time for the market to consider important positive announcements we have recently made as well as additional positive announcements expected during the extension period. We believe the good financial results from our year ended June 30, 2009 combined with the trend of five consecutive profitable quarters provide important momentum going into this extension period. We will also have the opportunity during the extension period to report our financial results for the quarter ending December 31, 2009. We trust these factors will all help us move toward regaining compliance with the NASDAQ requirement."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at http://www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements such as the statement regarding the opportunity to make future announcements and move toward regaining compliance with NASDAQ's minimum bid requirement. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2009.

SOURCE Dynatronics Corporation


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
2. Dynatronics Will Request Hearing With Nasdaq Regarding Listing Status
3. Dynatronics to Release First Quarter Results Friday, November 13, 2009; Conference Call Set for 1:30 p.m. ET
4. Dynatronics Announces Positive Financial Results for Quarter
5. Dynatronics Named Sole-Source Supplier to Benchmark Physical Therapy
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of ... Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. ... incentives to a patient’s remote health progress, empowering the patient to take direct responsibility ...
(Date:4/26/2017)... ... ... Infertility may be a result of an underlying pelvic ... become pregnant upon treating their diagnosis. , To properly diagnose patients, ... can provide the necessary information to diagnose and treat your problem. , ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn ... ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a ... food, with fewer resources. It highlights the business’ principles, research and collaboration efforts ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a ... announce that it has received 510(k) clearance from the U.S. Food & Drug ... MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
Breaking Medicine News(10 mins):